Unaudited Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2017		Dec. 31, 2016
Current Assets
Cash and cash equivalents (variable interest entity restricted - 2017: $24; 2016: $18)	$ 511		$ 638
Trade receivables - third party and affiliates (net of allowance for doubtful accounts - 2017: $7; 2016: $6; variable interest entity restricted - 2017: $5; 2016: $4)	985		801
Non-trade receivables, net	227		223
Inventories	771		720
Marketable securities, at fair value	30		30
Other assets	59		60
Total current assets	2,583		2,472
Investments in affiliates	885		852
Property, plant and equipment (net of accumulated depreciation - 2017: $2,419; 2016: $2,239; variable interest entity restricted - 2017: $714; 2016: $734)	3,663		3,577
Deferred income taxes	164		159
Other assets (variable interest entity restricted - 2017: $8; 2016: $9)	311		307
Goodwill	975	[1]	796
Intangible assets (variable interest entity restricted - 2017: $25; 2016: $26)	302		194
Total assets	8,883		8,357
Current Liabilities
Short-term borrowings and current installments of long-term debt - third party and affiliates	384		118
Trade payables - third party and affiliates	666		625
Other liabilities	332		322
Income taxes payable	42		12
Total current liabilities	1,424		1,077
Long-term debt, net of unamortized deferred financing costs	2,931		2,890
Deferred income taxes	165		130
Uncertain tax positions	150		131
Benefit obligations	866		893
Other liabilities	225		215
Commitments and Contingencies
Stockholders' Equity
Preferred stock, $0.01 par value, 100,000,000 shares authorized (2017 and 2016: 0 issued and outstanding)	0		0
Treasury stock, at cost (2017: 30,363,768 shares; 2016: 26,950,910 shares)	(1,834)		(1,531)
Additional paid-in capital	158		157
Retained earnings	4,617		4,320
Accumulated other comprehensive income (loss), net	(247)		(358)
Total Celanese Corporation stockholders' equity	2,694		2,588
Noncontrolling interests	428		433
Total equity	3,122		3,021
Total liabilities and equity	8,883		8,357
Series A common stock, $0.0001 par value, 400,000,000 shares authorized (2017: 168,018,535 issued and 137,654,767 outstanding; 2016: 167,611,357 issued and 140,660,447 outstanding)
Stockholders' Equity
Common stock	0		0
Series B common stock, $0.0001 par value, 100,000,000 shares authorized (2017 and 2016: 0 issued and outstanding)
Stockholders' Equity
Common stock	$ 0		$ 0

[1] There were $0 million of accumulated impairment losses as of June 30, 2017.